Amarin Corporation plc Overview
Pro stress-test →Amarin Corporation plc is a pharmaceutical company that engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Strategic Profile
Pro stress-test →The company sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. Amarin has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA.
Competitive Landscape
Pro stress-test →Amarin competes in the specialty cardiovascular pharmaceutical space against established players offering alternative triglyceride-lowering agents and lipid management therapies. Key competitors include major pharmaceutical companies with broader cardiovascular portfolios and other omega-3 or prescription lipid-focused manufacturers.
Industry Context
Amarin Corporation plc operates in Specialty cardiovascular pharmaceuticals.
Key facts
Founded: 1989 · Headquarters: Dublin, Ireland · Employees: 501–1000 · Revenue: N/A · Market cap: N/A